{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T19:43:47Z","timestamp":1774813427998,"version":"3.50.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI137410-01"],"award-info":[{"award-number":["1R01AI137410-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>RTS,S\/AS01 has been recommended by WHO for widespread implementation in medium to high malaria transmission settings. Previous analyses have noted lower vaccine efficacies in higher transmission settings, possibly due to the more rapid development of naturally acquired immunity in the control group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To investigate a reduced immune response to vaccination as a potential mechanism behind lower efficacy in high transmission areas, we examine initial vaccine antibody (anti-CSP IgG) response and vaccine efficacy against the first case of malaria (to exclude the effect of naturally acquired immunity) using data from three study areas (Kintampo, Ghana; Lilongwe, Malawi; Lambar\u00e9n\u00e9, Gabon) from the 2009\u20132014 phase III trial (NCT00866619). Our key exposures are parasitemia during the vaccination series and background malaria incidence. We calculate vaccine efficacy (one minus hazard ratio) using a cox-proportional hazards model and allowing for the time-varying effect of RTS,S\/AS01.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We find that antibody responses to the primary three-dose vaccination series were higher in Ghana than in Malawi and Gabon, but that neither antibody levels nor vaccine efficacy against the first case of malaria varied by background incidence or parasitemia during the primary vaccination series.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We find that vaccine efficacy is unrelated to infections during vaccination. Contributing to a conflicting literature, our results suggest that vaccine efficacy is also unrelated to infections before vaccination, meaning that control-group immunity is likely a major reason for lower efficacy in high transmission settings, not reduced immune responses to RTS,S\/AS01. This may be reassuring for implementation in high transmission settings, though further studies are needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08699-7","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T14:03:42Z","timestamp":1698069822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Background malaria incidence and parasitemia during the three-dose RTS,S\/AS01 vaccination series do not reduce magnitude of antibody response nor efficacy against the first case of malaria"],"prefix":"10.1186","volume":"23","author":[{"given":"Griffin J","family":"Bell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephaney","family":"Gyaase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Varun","family":"Goel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bright","family":"Adu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedicta","family":"Mensah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulin","family":"Essone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Dosoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Musah","family":"Osei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karamoko","family":"Niare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Wiru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Brandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Emch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Ghansah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwaku Poku","family":"Asante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tisungane","family":"Mvalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selidji Todagbe","family":"Agnandji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan J","family":"Juliano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,23]]},"reference":[{"key":"8699_CR1","unstructured":"Organization WH. Others. World malaria report 2021. 2021; Available from: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/350147\/9789240040496-eng.pdf?sequence=1."},{"key":"8699_CR2","doi-asserted-by":"crossref","unstructured":"Efficacy and safety of, RTS. S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386(9988):31\u201345.","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"8699_CR3","doi-asserted-by":"publisher","unstructured":"Bell GJ, Agnandji ST, Asante KP, Ghansah A, Kamthunzi P, Emch M et al. Impacts of Ecology, Parasite Antigenic Variation, and Human Genetics on RTS,S\/AS01e Malaria Vaccine Efficacy. Current Epidemiology Reports [Internet]. 2021; https:\/\/doi.org\/10.1007\/s40471-021-00271-8.","DOI":"10.1007\/s40471-021-00271-8"},{"issue":"1","key":"8699_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12936-022-04098-6","volume":"21","author":"B Greenwood","year":"2022","unstructured":"Greenwood B, Zongo I, Dicko A, Chandramohan D, Snow RW, Ockenhouse C. Resurgent and delayed Malaria. Malar J. 2022;21(1):77.","journal-title":"Malar J"},{"key":"8699_CR5","doi-asserted-by":"publisher","unstructured":"Bell GJ, Goel V, Essone P, Dosoo D, Adu B, Mensah BA et al. Malaria Transmission Intensity Likely Modifies RTS, S\/AS01 Efficacy Due to a Rebound Effect in Ghana, Malawi, and Gabon. J Infect Dis [Internet]. 2022; https:\/\/doi.org\/10.1093\/infdis\/jiac322.","DOI":"10.1093\/infdis\/jiac322"},{"issue":"8","key":"8699_CR6","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S1473-3099(19)30300-7","volume":"19","author":"H Tinto","year":"2019","unstructured":"Tinto H, Otieno W, Gesase S, Sorgho H, Otieno L, Liheluka E, et al. Long-term incidence of severe Malaria following RTS,S\/AS01 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Lancet Infect Dis. 2019;19(8):821\u201332.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"8699_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12916-019-1277-x","volume":"17","author":"L Kurtovic","year":"2019","unstructured":"Kurtovic L, Agius PA, Feng G, Drew DR, Ubillos I, Sacarlal J, et al. Induction and decay of functional complement-fixing antibodies by the RTS,S Malaria vaccine in children, and a negative impact of Malaria exposure. BMC Med. 2019;17(1):45.","journal-title":"BMC Med"},{"issue":"1","key":"8699_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12916-022-02466-2","volume":"20","author":"G Feng","year":"2022","unstructured":"Feng G, Kurtovic L, Agius PA, Aitken EH, Sacarlal J, Wines BD, et al. Induction, decay, and determinants of functional antibodies following vaccination with the RTS,S Malaria vaccine in young children. BMC Med. 2022;20(1):289.","journal-title":"BMC Med"},{"issue":"1","key":"8699_CR9","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12916-018-1186-4","volume":"16","author":"I Ubillos","year":"2018","unstructured":"Ubillos I, Ayestaran A, Nhabomba AJ, Dosoo D, Vidal M, Jim\u00e9nez A, et al. Baseline exposure, antibody subclass, and Hepatitis B response differentially affect Malaria protective immunity following RTS,S\/AS01E vaccination in African children. BMC Med. 2018;16(1):197.","journal-title":"BMC Med"},{"issue":"5","key":"8699_CR10","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1093\/cid\/cix429","volume":"65","author":"G Moncunill","year":"2017","unstructured":"Moncunill G, Mpina M, Nhabomba AJ, Aguilar R, Ayestaran A, Sanz H, et al. Distinct helper T cell type 1 and 2 responses Associated with Malaria Protection and Risk in RTS,S\/AS01E vaccinees. Clin Infect Dis. 2017;65(5):746\u201355.","journal-title":"Clin Infect Dis"},{"key":"8699_CR11","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fmicb.2014.00249","volume":"5","author":"MN Wykes","year":"2014","unstructured":"Wykes MN, Horne-Debets JM, Leow C-Y, Karunarathne DS. Malaria drives T cells to exhaustion. Front Microbiol. 2014;5:249.","journal-title":"Front Microbiol"},{"issue":"9","key":"8699_CR12","doi-asserted-by":"publisher","first-page":"eaay9269","DOI":"10.1126\/sciadv.aay9269","volume":"6","author":"Y Fu","year":"2020","unstructured":"Fu Y, Ding Y, Wang Q, Zhu F, Tan Y, Lu X, et al. Blood-stage Malaria parasites manipulate host innate immune responses through the induction of sFGL2. Sci Adv. 2020;6(9):eaay9269.","journal-title":"Sci Adv"},{"issue":"5","key":"8699_CR13","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.celrep.2013.11.002","volume":"5","author":"JM Horne-Debets","year":"2013","unstructured":"Horne-Debets JM, Faleiro R, Karunarathne DS, Liu XQ, Lineburg KE, Poh CM, et al. PD-1 dependent exhaustion of CD8 + T cells drives chronic Malaria. Cell Rep. 2013;5(5):1204\u201313.","journal-title":"Cell Rep"},{"issue":"3","key":"8699_CR14","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.4049\/jimmunol.1202438","volume":"190","author":"J Illingworth","year":"2013","unstructured":"Illingworth J, Butler NS, Roetynck S, Mwacharo J, Pierce SK, Bejon P, et al. Chronic exposure to Plasmodium Falciparum is associated with phenotypic evidence of B and T cell exhaustion. J Immunol. 2013;190(3):1038\u201347.","journal-title":"J Immunol"},{"issue":"6","key":"8699_CR15","doi-asserted-by":"publisher","first-page":"e0009361","DOI":"10.1371\/journal.pntd.0009361","volume":"15","author":"O Nouatin","year":"2021","unstructured":"Nouatin O, Mengue JB, Dejon-Agob\u00e9 JC, Fendel R, Ib\u00e1\u00f1ez J, Ngoa UA, et al. Exploratory analysis of the effect of helminth Infection on the immunogenicity and efficacy of the asexual blood-stage Malaria vaccine candidate GMZ2. PLoS Negl Trop Dis. 2021;15(6):e0009361.","journal-title":"PLoS Negl Trop Dis"},{"issue":"4","key":"8699_CR16","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1128\/IAI.74.4.2138-2144.2006","volume":"74","author":"Z Su","year":"2006","unstructured":"Su Z, Segura M, Stevenson MM. Reduced protective efficacy of a blood-stage Malaria vaccine by concurrent nematode Infection. Infect Immun. 2006;74(4):2138\u201344.","journal-title":"Infect Immun"},{"issue":"4","key":"8699_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1586\/erv.10.16","volume":"9","author":"AJ Cunnington","year":"2010","unstructured":"Cunnington AJ, Riley EM. Suppression of vaccine responses by Malaria: insignificant or overlooked? Expert Rev Vaccines. 2010;9(4):409\u201329.","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"8699_CR18","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12916-019-1378-6","volume":"17","author":"C Doba\u00f1o","year":"2019","unstructured":"Doba\u00f1o C, Ubillos I, Jairoce C, Gyan B, Vidal M, Jim\u00e9nez A, et al. RTS,S\/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical Malaria in African children: a case-control study. BMC Med. 2019;17(1):157.","journal-title":"BMC Med"},{"issue":"10","key":"8699_CR19","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/cid\/cit556","volume":"57","author":"J Rono","year":"2013","unstructured":"Rono J, Osier FHA, Olsson D, Montgomery S, Mhoja L, Rooth I, et al. Breadth of anti-merozoite antibody responses is associated with the genetic diversity of asymptomatic Plasmodium falciparum Infections and protection against clinical Malaria. Clin Infect Dis. 2013;57(10):1409\u201316.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"8699_CR20","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.vaccine.2020.12.055","volume":"39","author":"S Chaudhury","year":"2021","unstructured":"Chaudhury S, MacGill RS, Early AM, Bolton JS, King CR, Locke E, et al. Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S Malaria vaccine. Vaccine. 2021;39(6):968\u201375.","journal-title":"Vaccine"},{"issue":"9","key":"8699_CR21","doi-asserted-by":"publisher","first-page":"e0256980","DOI":"10.1371\/journal.pone.0256980","volume":"16","author":"MJ Sklar","year":"2021","unstructured":"Sklar MJ, Maiolatesi S, Patterson N, Sedegah M, Limbach K, Teneza-Mora N, et al. A three-antigen Plasmodium Falciparum DNA prime-adenovirus boost Malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human Malaria Infection in healthy malaria-na\u00efve adults. PLoS ONE. 2021;16(9):e0256980.","journal-title":"PLoS ONE"},{"issue":"45","key":"8699_CR22","doi-asserted-by":"publisher","first-page":"12045","DOI":"10.1073\/pnas.1702944114","volume":"114","author":"LY Bustamante","year":"2017","unstructured":"Bustamante LY, Powell GT, Lin Y-C, Macklin MD, Cross N, Kemp A, et al. Synergistic Malaria vaccine combinations identified by systematic antigen screening. Proc Natl Acad Sci U S A. 2017;114(45):12045\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"8699_CR23","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","volume":"15","author":"MT White","year":"2015","unstructured":"White MT, Verity R, Griffin JT, Asante KP, Owusu-Agyei S, Greenwood B, et al. Immunogenicity of the RTS,S\/AS01 Malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015;15(12):1450\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"8699_CR24","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1371\/journal.pmed.0030473","volume":"3","author":"SI Hay","year":"2006","unstructured":"Hay SI, Snow RW. The Malaria Atlas Project: developing global maps of Malaria risk. PLoS Med. 2006;3(12):e473.","journal-title":"PLoS Med"},{"issue":"12","key":"8699_CR25","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.vaccine.2018.01.069","volume":"36","author":"CM Nielsen","year":"2018","unstructured":"Nielsen CM, Vekemans J, Lievens M, Kester KE, Regules JA, Ockenhouse CF. RTS,S Malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype. Vaccine. 2018;36(12):1637\u201342.","journal-title":"Vaccine"},{"issue":"4","key":"8699_CR26","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.4049\/jimmunol.1701010","volume":"200","author":"JE Schrum","year":"2018","unstructured":"Schrum JE, Crabtree JN, Dobbs KR, Kiritsy MC, Reed GW, Gazzinelli RT, et al. Cutting Edge: Plasmodium Falciparum induces trained innate immunity. J Immunol. 2018;200(4):1243\u20138.","journal-title":"J Immunol"},{"issue":"4","key":"8699_CR27","doi-asserted-by":"publisher","first-page":"e61395","DOI":"10.1371\/journal.pone.0061395","volume":"8","author":"MT White","year":"2013","unstructured":"White MT, Bejon P, Olotu A, Griffin JT, Riley EM, Kester KE, et al. The relationship between RTS,S Vaccine-Induced antibodies, CD4 + T cell responses and Protection against Plasmodium falciparum Infection. PLoS ONE. 2013;8(4):e61395.","journal-title":"PLoS ONE"},{"issue":"4","key":"8699_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1473-3099(13)70005-7","volume":"13","author":"P Bejon","year":"2013","unstructured":"Bejon P, White MT, Olotu A, Bojang K, Lusingu JPA, Salim N, et al. Efficacy of RTS,S Malaria vaccines: individual-participant pooled analysis of phase 2 data. Lancet Infect Dis. 2013;13(4):319\u201327.","journal-title":"Lancet Infect Dis"},{"issue":"26","key":"8699_CR29","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1515257","volume":"374","author":"A Olotu","year":"2016","unstructured":"Olotu A, Fegan G, Wambua J, Nyangweso G, Leach A, Lievens M, et al. Seven-year efficacy of RTS,S\/AS01 Malaria vaccine among young African children. N Engl J Med. 2016;374(26):2519\u201329.","journal-title":"N Engl J Med"},{"issue":"12","key":"8699_CR30","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMoa1207564","volume":"368","author":"A Olotu","year":"2013","unstructured":"Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo KO, Leach A, et al. Four-year efficacy of RTS, S\/AS01E and its interaction with Malaria exposure. N Engl J Med. 2013;368(12):1111\u201320.","journal-title":"N Engl J Med"},{"issue":"1","key":"8699_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-019-10195-z","volume":"10","author":"C Doba\u00f1o","year":"2019","unstructured":"Doba\u00f1o C, Sanz H, Sorgho H, Dosoo D, Mpina M, Ubillos I, et al. Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS, S\/AS01E Malaria vaccine efficacy. Nat Commun. 2019;10(1):1\u201313.","journal-title":"Nat Commun"},{"issue":"1","key":"8699_CR32","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1038\/s41598-019-39698-x","volume":"9","author":"KE Langwig","year":"2019","unstructured":"Langwig KE, Gomes MGM, Clark MD, Kwitny M, Yamada S, Wargo AR, et al. Limited available evidence supports theoretical predictions of reduced vaccine efficacy at higher exposure dose. Sci Rep. 2019;9(1):3203.","journal-title":"Sci Rep"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08699-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08699-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T06:05:35Z","timestamp":1700460335000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08699-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,23]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8699"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08699-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,23]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a secondary analysis of phase III clinical trial data (NCT00866619). The trial protocol was approved by the ethical review board at each study center and partner institution and by the national regulatory authority in each country and the trial was undertaken in accordance with the provisions of the Good Clinical Practice Guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflicts of interest. GlaxoSmithKline Biologicals SA was provided the opportunity to review a preliminary version of this manuscript for factual accuracy, but the authors are solely responsible for final content and interpretation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"716"}}